Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models

Cell Adhesion and Migration

Volumn 3, Issue 1, 2009, Pages 129-137

  He, Jue ^a,b   Kong, Jiming ^b   Tan, Qing Rong ^a   Li, Xin Min ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anxiety like behavior; Atypical antipsychotics; Memory; Neuroprotective effect; Neurotoxicity

Indexed keywords

AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; METHAMPHETAMINE; OKADAIC ACID; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ANXIETY DISORDER; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BRAIN ISCHEMIA; CELL DEATH; COGNITION; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; HUMAN; MEMORY DISORDER; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROCHEMISTRY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REVIEW; SCHIZOPHRENIA; STROKE; UPREGULATION;

ANIMALIA;

EID: 67049101057     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.3.1.7401     Document Type: Review

References (137)

1. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002; 53:239-248
2. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26:137-149 (Pubitemid 32373127)
3. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: An overview of pivotal clinical trials. J Clin Psychiatry 1997; 58:7-12. (Pubitemid 27333174)
4. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: A longitudinal study. Schizophr Res 2001; 48:17-28. (Pubitemid 32241180)
5. Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: Neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 2004; 24:1759-1783 (Pubitemid 39578963)
6. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:275-282 (Pubitemid 44959242)
7. Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008; 23:1-8. (Pubitemid 350294864)
8. Madhusoodanan S, Shah P, Brenner R, Gupta S. Pharmacological treatment of the psychosis of alzheimer's disease: What is the best approach? CNS Drugs 2007; 21:101-115
9. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. Effects of olanzapine, quetiapine and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164:1061-1071 (Pubitemid 47121395)
10. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in parkinson's disease. Mov Disord 2004; 19:29-35. (Pubitemid 38559617)
11. Wong AH, Van Tol HH. Schizophrenia: From phenomenology to neurobiology. Neurosci Biobehav Rev 2003; 27:269-306.
12. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293
13. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156:876-884 (Pubitemid 29260342)
14. Woods BT, Yurgelun-Todd D, Benes FM, Frankenburg FR, Pope HG Jr, McSparren J. Progressive ventricular enlargement in schizophrenia: Comparison to bipolar affective disorder and correlation with clinical course. Biol Psychiatry 1990; 27:341-352 (Pubitemid 20055790)
15. Waddington JL, O'Callaghan E, Buckley P, Larkin C, Redmond O, Stack J, et al. The age dependencies of MRI abnormalities in schizophrenia suggest early ventricular enlargement but later prominence of cortical atrophy. Schizophr Res 1991; 5:188-189
16. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 1997; 74:129-140 (Pubitemid 27315863)
17. Arnold SE, Trojanowski JQ. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol 1996; 92:217-231 (Pubitemid 26278952)
18. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321-330
19. Harvey PD. Comprehensive clinical psychology. In: Bellack AS, Hersen M, eds. Schizophrenia and related disorders in late life. Amsterdam: Elsevier 1998; 74-86.
20. He J, Xu H, Yang Y, Zhang X, Li XM. Neuroprotective effects of olanzapine on methamphetamine- induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of bcl-2 decrease in rats. Brain Res 2004; 1018:186-192 (Pubitemid 38992818)
21. He J, Yang Y, Yu Y, Li X, Li XM. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav Brain Res 2006; 172:39-45. (Pubitemid 44037816)
22. He J, Xu H, Yang Y, Zhang X, Li XM. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav Brain Res 2005; 160:178-187 (Pubitemid 40504168)
23. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of bcl- XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 2006; 168:236-242 (Pubitemid 43201940)
24. Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005; 1063:32-39 (Pubitemid 41628205)
25. Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res 2002; 69:278-283 (Pubitemid 34734158)
26. +-induced apoptosis. Eur J Neurosci 2003; 17:1563-1570
27. Wei Z, Bai O, Richardson JS, Mousseau DD, Li XM. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res 2003; 73:364-368 (Pubitemid 36918100)
28. Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating bax and bcl-X(l/s) expression and localization. J Neurosci Res 2003; 74:942-947
29. Cancela LM, Basso AM, Martijena ID, Capriles NR, Molina VA. A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: A behavioral and neurochemical study. Brain Res 2001; 909:179-186
30. Lapin IP. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plusmaze in mice and its attenuation by ethanol. Pharmacol Biochem Behav 1993; 44:241-243 (Pubitemid 23025314)
31. Lin HQ, Burden PM, Christie MJ, Johnston GA. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: A comparison with amphetamine. Pharmacol Biochem Behav 1999; 62:403-408 (Pubitemid 29117180)
32. Simon P, Panissaud C, Costentin J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol Biochem Behav 1993; 45:685-690 (Pubitemid 23174012)
33. Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology (Berl) 1995; 118:316-323
34. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987; 92:180-185 (Pubitemid 17072893)
35. Abekawa T, Ohmori T, Koyama T. Tolerance to the neurotoxic effect of methamphetamine in rats behaviorally sensitized to methamphetamine or amphetamine. Brain Res 1997; 767:34-44. (Pubitemid 27428549)
36. Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: Dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 1998; 30:433-445 (Pubitemid 28506998)
37. Ellison G, Eison MS, Huberman HS, Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 1978; 201:276-278 (Pubitemid 8396757)
38. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis - preliminary observations. Biol Psychiatry 1970; 2:95-107.
39. Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: Behavioral and biochemical aspects. J Psychiatr Res 1974; 11:13-23.
40. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997; 53:281-298 (Pubitemid 27073117)
41. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48:253-273 (Pubitemid 24260357)
42. Mechanic JA, Wasielewski JA, Carl KL, Holloway FA. Attenuation of the amphetamine discriminative cue in rats with the atypical antipsychotic olanzapine. Pharmacol Biochem Behav 2002; 72:767-777 (Pubitemid 34624647)
43. Rush CR, Stoops WW, Hays LR, Glaser PE, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003; 306:195-204. (Pubitemid 36734373)
44. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. implications for atypical antipsychotic action. J Psychiatry Neurosci 2000; 25:161-166 (Pubitemid 30233553)
45. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68:29-39.
46. Briley M, Chopin P, Moret C. Effect of serotonergic lesion on "anxious" behaviour measured in the elevated plus-maze test in the rat. Psychopharmacology (Berl) 1990; 101:187-189
47. Tye NC, Everitt BJ, Iversen SD. 5-hydroxytryptamine and punishment. Nature 1977; 268:741-743
48. Tye NC, Iversen SD, Green AR. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979; 18:689-695 (Pubitemid 9251017)
49. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004; 1010:81-86 (Pubitemid 38569855)
50. Luo C, Xu H, Li XM. Post-stress changes in BDNF and bcl-2 immunoreactivities in hippocampal neurons: Effect of chronic administration of olanzapine. Brain Res 2004; 1025:194-202. (Pubitemid 39349538)
51. Xu H, Qing H, Lu W, Keegan D, Richardson JS, Chlan-Fourney J, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002; 321:65-68 (Pubitemid 34185500)
52. Albers DS, Sonsalla PK. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 1995; 275:1104-1114 (Pubitemid 26129911)
53. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr, et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994; 268:1571-1580 (Pubitemid 24100380)
54. Farfel GM, Seiden LS. Role of hypothermia in the mechanism of protection against serotonergic toxicity I. experiments using 3,4- methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther 1995; 272:860-867
55. Miller DB, O'Callaghan JP. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270:752-760 (Pubitemid 24271392)
56. Schmidt CJ, Black CK, Abbate GM, Taylor VL. Methylenedioxymethamphetamineinduced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 1990; 529:85-90. (Pubitemid 20326842)
57. Lan KC, Lin YF, Yu FC, Lin CS, Chu P. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 1998; 97:528-533 (Pubitemid 28414522)
58. O'Dell SJ, Weihmuller FB, Marshall JF. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res 1991; 564:256-260
59. Wallace TL, Gudelsky GA, Vorhees CV. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior and stimulated dopamine release in the rat. J Neurosci 1999; 19:9141-9148 (Pubitemid 30226734)
60. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 2001; 36:1-22. (Pubitemid 32763126)
61. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W. Cognitive impairment in individuals currently using methamphetamine. Am J Addict 2000; 9:222-231
62. Bisagno V, Ferguson D, Luine VN. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res 2002; 940:95-101. (Pubitemid 34525091)
63. Schroder N, O'Dell SJ, Marshall JF. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse 2003; 49:89-96. (Pubitemid 36702718)
64. Jayanthi S, Deng X, Bordelon M, McCoy MT, Cadet JL. Methamphetamine causes differential regulation of pro-death and anti-death bcl-2 genes in the mouse neocortex. FASEB J 2001; 15:1745-1752 (Pubitemid 32730222)
65. Cadet JL, Ordonez SV, Ordonez JV. Methamphetamine induces apoptosis in immortalized neural cells: Protection by the proto-oncogene, bcl-2. Synapse 1997; 25:176-184 (Pubitemid 27121228)
66. Kita T, Wagner GC, Nakashima T. Current research on methamphetamine- induced neurotoxicity: Animal models of monoamine disruption. J Pharmacol Sci 2003; 92:178-195 (Pubitemid 36992304)
67. Howard S, Bottino C, Brooke S, Cheng E, Giffard RG, Sapolsky R. Neuroprotective effects of bcl-2 overexpression in hippocampal cultures: Interactions with pathways of oxidative damage. J Neurochem 2002; 83:914-923 (Pubitemid 35316042)
68. Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from betaamyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 2005; 81:572-580
69. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, Holson RR. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 1992; 260:817-824
70. Fukumura M, Cappon GD, Pu C, Broening HW, Vorhees CV. A single dose model of methamphetamine-induced neurotoxicity in rats: Effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res 1998; 806:1-7. (Pubitemid 29009568)
71. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 1987; 9:12-35.
72. Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl) 2004; 175:310-318 (Pubitemid 39366025)
73. Handelmann GE, Contreras PC, O'Donohue TL. Selective memory impairment by phencyclidine in rats. Eur J Pharmacol 1987; 140:69-73. (Pubitemid 17133747)
74. Kesner RP, Dakis M, Bolland BL. Phencyclidine disrupts long- but not short-term memory within a spatial learning task. Psychopharmacology (Berl) 1993; 111:85-90. (Pubitemid 23101356)
75. Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res 1997; 752:1-14. (Pubitemid 27143892)
76. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244:1360-1362 (Pubitemid 19170513)
77. Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, et al. Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 1994; 62:1079-1092 (Pubitemid 24335603)
78. Mitchell IJ, Cooper AJ, Griffiths MR, Barber DJ. Phencyclidine and corticosteroids induce apoptosis of a subpopulation of striatal neurons: A neural substrate for psychosis? Neuroscience 1998; 84:489-501.
79. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Longterm behavioral and neurodegenerative effects of perinatal phencyclidine administration: Implications for schizophrenia. Neuroscience 2001; 107:535-550 (Pubitemid 33097492)
80. Adams JM, Cory S. The bcl-2 protein family: Arbiters of cell survival. Science 1998; 281:1322-1326 (Pubitemid 28406819)
81. Wang C, Kaufmann JA, Sanchez-Ross MG, Johnson KM. Mechanisms of N-methyl- D-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons. J Pharmacol Exp Ther 2000; 294:287-295 (Pubitemid 30434699)
82. Pandya DN, Yeterian EH. Proposed neural circuitry for spatial memory in the primate brain. Neuropsychologia 1984; 22:109-122 (Pubitemid 14139616)
83. Sutherland RJ, Whishaw IQ, Kolb B. Contributions of cingulate cortex to two forms of spatial learning and memory. J Neurosci 1988; 8:1863-1872 (Pubitemid 18162696)
84. Griffiths MR, Cooper AJ, Barber DJ, Mitchell IJ. Pharmacological mechanisms mediating phencyclidine-induced apoptosis of striatopallidal neurons: The roles of glutamate, dopamine, acetylcholine and corticosteroids. Brain Res 2000; 855:1-10. (Pubitemid 30067688)
85. Hertel P, Mathe JM, Nomikos GG, Iurlo M, Mathe AA, Svensson TH. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 1995; 72:103-114
86. Farber NB, Price MT, Labruyere J, Nemnich J, St. Peter H, Wozniak DF, et al. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 1993; 34:119-121 (Pubitemid 23240031)
87. Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry 1994; 55:43-46 (Pubitemid 24353015)
88. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; 47:27-38. (Pubitemid 34302921)
89. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003; 71:127-131 (Pubitemid 36008409)
90. Ishihara H, Martin BL, Brautigan DL, Karaki H, Ozaki H, Kato Y, et al. Calyculin A and okadaic acid: Inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 1989; 159:871-877 (Pubitemid 19101063)
91. Cohen P, Holmes CF, Tsukitani Y. Okadaic acid: A new probe for the study of cellular regulation. Trends Biochem Sci 1990; 15:98-102. (Pubitemid 20067990)
92. Cagnoli CM, Kharlamov E, Atabay C, Uz T, Manev H. Apoptosis induced in neuronal cultures by either the phosphatase inhibitor okadaic acid or the kinase inhibitor staurosporine is attenuated by isoquinolinesulfonamides H-7, H-8 and H-9. J Mol Neurosci 1996; 7:65-76. (Pubitemid 126718436)
93. Van Dam AM, Bol JG, Binnekade R, van Muiswinkel FL. Acute or chronic administration of okadaic acid to rats induces brain damage rather than alzheimer-like neuropathology. Neuroscience 1998; 85:1333-1335 (Pubitemid 28293434)
94. He J, Yamada K, Zou LB, Nabeshima T. Spatial memory deficit and neurodegeneration induced by the direct injection of okadaic acid into the hippocampus in rats. J Neural Transm 2001; 108:1435-1443 (Pubitemid 34020447)
95. Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Phosphorylation of tau, abetaformation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiol Aging 1998; 19:3-13. (Pubitemid 28167790)
96. Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 1995; 69:691-698
97. Zhao W, Bennett P, Sedman GL, NG KT. The impairment of long-term memory formation by the phosphatase inhibitor okadaic acid. Brain Res Bull 1995; 36:557-561
98. Tian Q, Lin ZQ, Wang XC, Chen J, Wang Q, Gong CX, et al. Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience 2004; 126:277-284 (Pubitemid 38780803)
99. He J, Yang Y, Xu H, Zhang X, Li XM. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology 2005; 30:1511-1520 (Pubitemid 41153123)
100. Sweatt JD. Hippocampal function in cognition. Psychopharmacology (Berl) 2004; 174:99-110. (Pubitemid 38925095)
101. Alvarado MC, Bachevalier J. Selective neurotoxic damage to the hippocampal formation impairs performance of the transverse patterning and location memory tasks in rhesus macaques. Hippocampus 2005; 15:118-131 (Pubitemid 40340248)
102. Benito A, Lerga A, Silva M, Leon J, Fernandez-Luna JL. Apoptosis of human myeloid leukemia cells induced by an inhibitor of protein phosphatases (okadaic acid) is prevented by bcl-2 and bcl-X(L). Leukemia 1997; 11:940-944
103. Cabado AG, Leira F, Vieytes MR, Vieites JM, Botana LM. Cytoskeletal disruption is the key factor that triggers apoptosis in okadaic acid-treated neuroblastoma cells. Arch Toxicol 2004; 78:74-85. (Pubitemid 38316662)
104. Nuydens R, Dispersyn G, Van Den Keiboom G, de Jong M, Connors R, Ramaekers F, et al. Bcl-2 protects against apoptosis-related microtubule alterations in neuronal cells. Apoptosis 2000; 5:43-51. (Pubitemid 30146389)
105. Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem 1998; 273:13245-13254 (Pubitemid 28246897)
106. Li XM, Chlan-Fourney J, Juorio AV, Bennett VL, Shrikhande S, Keegan DL, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res 1999; 56:72-75 (Pubitemid 29190618)
107. Matias WG, Traore A, Bonini M, Sanni A, Creppy EE. Oxygen reactive radicals production in cell culture by okadaic acid and their implication in protein synthesis inhibition. Hum Exp Toxicol 1999; 18:634-639 (Pubitemid 29531305)
108. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002; 26:325-339 (Pubitemid 34159210)
109. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002; 26:583-594 (Pubitemid 34260977)
110. Kurz AF. Uncommon neurodegenerative causes of dementia. Int Psychogeriatr 2005; 17:35-49. (Pubitemid 44561754)
111. Nunn JA, LePeillet E, Netto CA, Hodges H, Gray JA, Meldrum BS. Global ischaemia: Hippocampal pathology and spatial deficits in the water maze. Behav Brain Res 1994; 62:41-54. (Pubitemid 24171559)
112. Chemerinski E, Levine SR. Neuropsychiatric disorders following vascular brain injury. Mt Sinai J Med 2006; 73:1006-1014 (Pubitemid 46040399)
113. Williams LS, Ghose SS, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry 2004; 161:1090-1095 (Pubitemid 38735996)
114. Bokura H, Robinson RG. Long-term cognitive impairment associated with caudate stroke. Stroke 1997; 28:970-975 (Pubitemid 27209143)
115. Bradvik B, Sonesson B, Holtas S. Spatial impairment following right hemisphere transient ischaemic attacks in patients without carotid artery stenosis. Acta Neurol Scand 1989; 80:411-418 (Pubitemid 19273196)
116. Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic stroke: Results of a longitudinal study. Stroke 2002; 33:2254-2260 (Pubitemid 35014639)
117. Desmond DW, Moroney JT, Sano M, Stern Y. Mortality in patients with dementia after ischemic stroke. Neurology 2002; 59:537-543 (Pubitemid 34919986)
118. Martin LJ. Neuronal cell death in nervous system development, disease and injury (review). Int J Mol Med 2001; 7:455-478
119. Caccamo D, Campisi A, Curro M, Li Volti G, Vanella A, Ientile R. Excitotoxic and post-ischemic neurodegeneration: Involvement of transglutaminases. Amino Acids 2004; 27:373-379 (Pubitemid 40110083)
120. Hartman RE, Lee JM, Zipfel GJ, Wozniak DF. Characterizing learning deficits and hippocampal neuron loss following transient global cerebral ischemia in rats. Brain Res 2005; 1043:48-56. (Pubitemid 40603371)
121. Jaspers RM, Block F, Heim C, Sontag KH. Spatial learning is affected by transient occlusion of common carotid arteries (2VO): Comparison of behavioural and histopathological changes after '2VO' and 'four-vessel-occlusion' in rats. Neurosci Lett 1990; 117:149-153
122. Yan B, Bi X, He J, Zhang Y, Thakur S, Xu H, et al. Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice. Life Sci 2007; 81:353-361 (Pubitemid 47082443)
123. Yan B, He J, Xu H, Zhang Y, Bi X, Thakur S, et al. Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behav Brain Res 2007; 182:36-41. (Pubitemid 47042189)
124. Yan B, Wang DY, Xing DM, Ding Y, Wang RF, Lei F, et al. The antidepressant effect of ethanol extract of radix puerariae in mice exposed to cerebral ischemia reperfusion. Pharmacol Biochem Behav 2004; 78:319-325 (Pubitemid 38829368)
125. Bryer JB, Starkstein SE, Votypka V, Parikh RM, Price TR, Robinson RG. Reduction of CSF monoamine metabolites in poststroke depression: A preliminary report. J Neuropsychiatry Clin Neurosci 1992; 4:440-442
126. Mayberg HS, Parikh RM, Morris PL, Robinson RG. Spontaneous remission of post-stroke depression and temporal changes in cortical S2-serotonin receptors. J Neuropsychiatry Clin Neurosci 1991; 3:80-83
127. Yuen EC, Mobley WC. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 1996; 40:346-354 (Pubitemid 26304792)
128. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor levels in never medicated first episode psychotic patients and medicated chronic schizophrenic patients. Schizophr Res 2003; 60:117-123 (Pubitemid 36187455)
129. Fumagalli F, Molteni R, Bedogni, F, Gennarelli M, Perez J, Racagni G, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. NeuroReport 2004; 15:2109-2112 (Pubitemid 39281756)
130. Bruckheimer EM, Cho SH, Sarkiss M, Herrmann J, McDonnell TJ. The bcl-2 gene family and apoptosis. Adv Biochem Eng Biotechnol 1998; 62:75-105.
131. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62:361-370 (Pubitemid 40471685)
132. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005; 28:223-250 (Pubitemid 41098905)
133. Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004; 56:570-580 (Pubitemid 39336404)
134. Wakade CG, Mahadik SP, Waller JL, Chiu FC. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002; 69:72-79 (Pubitemid 34734166)
135. Roy NS, Wang S, Jiang L, Kang J, Benraiss A, Harrison-Restelli C, et al. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat Med 2000; 6:271-277
136. Bruel-Jungerman E, Rampon C, Laroche S. Adult hippocampal neurogenesis, synaptic plasticity and memory: Facts and hypotheses. Rev Neurosci 2007; 18:93-114.
137. Newton SS, Duman RS. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 2007; 21:715-725 (Pubitemid 47294718)